Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
targeting HLA-DP4/WT1 in T cell receptor gene therapy for acute myelogenous leukemia
EF 2015-16
Résumé
Cancer is the leading cause of death in Canada. T cells, a major component of our immune system, play key role in control and elimination of cancerous cells through recognition of tumor-associated complex by T cell receptor (TCR). Genetically-modified T cells expressing antitumor TCRs on the cell surface can be adoptively transferred into cancer patients and significant clinical responses have been reported. However, antitumor TCRs can also cross-react with other complexes expressed on the surface of normal cells, which can induce unwanted adverse effects. Also, most antitumor TCRs possess insufficient affinity and cannot recognize tumor cells effectively. Recently, by manipulating TCRs at the gene level, we have developed a method to isolate TCRs with a broad range of cross-reactivity and antitumor affinity. Wilms tumor 1 (WT1) is a protein over-expressed in various types of cancer including leukemias but not in normal cells. Also, level of WT1 is correlated with disease aggressiveness and poor prognosis. These observations have prompted many researchers to develop immunotherapy targeting WT1, as several clinical trials have been conducted. Here, our goal is to employ the pre-established method to isolate WT1-specific TCRs with minimal cross-reactivity and optimal antitumor affinity. These TCRs can be utilized in TCR gene therapy, which can serve as a promising therapeutic strategy against many types of cancer and benefit substantial number of cancer patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
350160
Name
Wang Chung-Hsi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
targeting HLA-DP4/WT1 in T cell receptor gene therapy for acute myelogenous leukemia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cd4+ T Cell Theapy; Cancer; Chain-Centricity; Cross-Reactivity; Hla-Dp4; Immunotherapy; Leukemia; Tcr Affinity; Tcr Gene Therapy; Wt1
Abstract
Cancer is the leading cause of death in Canada. T cells, a major component of our immune system, play key role in control and elimination of cancerous cells through recognition of tumor-associated complex by T cell receptor (TCR). Genetically-modified T cells expressing antitumor TCRs on the cell surface can be adoptively transferred into cancer patients and significant clinical responses have been reported. However, antitumor TCRs can also cross-react with other complexes expressed on the surface of normal cells, which can induce unwanted adverse effects. Also, most antitumor TCRs possess insufficient affinity and cannot recognize tumor cells effectively. Recently, by manipulating TCRs at the gene level, we have developed a method to isolate TCRs with a broad range of cross-reactivity and antitumor affinity. Wilms tumor 1 (WT1) is a protein over-expressed in various types of cancer including leukemias but not in normal cells. Also, level of WT1 is correlated with disease aggressiveness and poor prognosis. These observations have prompted many researchers to develop immunotherapy targeting WT1, as several clinical trials have been conducted. Here, our goal is to employ the pre-established method to isolate WT1-specific TCRs with minimal cross-reactivity and optimal antitumor affinity. These TCRs can be utilized in TCR gene therapy, which can serve as a promising therapeutic strategy against many types of cancer and benefit substantial number of cancer patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Chung-Hsi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~